Clinical Trial Update: Adjunctive, Low-dose tPA in Primary PCI for STEMI [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating adjunctive, low-dose tissue plasminogen activator during primary percutaneous coronary intervention for ST-elevation myocard…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• Alteplase (alteplase)

Snippet

Sponsor: Population Health Research Institute | Conditions: Myocardial Infarction, Percutaneous Coronary Intervention | Phase 3 | Status: COMPLETED